Lead Plaintiff Deadline is Approaching - Act Now

BioAge Labs Inc.® Class Action

Soto v. BioAge Labs, Inc. et al.

BioAge Labs Inc

NASDAQ: BIOA

Class Period : 09/22/2024 - 01/07/2025

Lead Plaintiff Motion Deadline: 3/10/2025

Alleged Misstatements and Omissions
The BioAge® class action lawsuit claims the company misled investors by making false and/or misleading statements and omitting critical information in its IPO offering documents. Key allegations include:

  • Safety Claims for Azelaprag: The IPO prospectus described the lead drug candidate, azelaprag, as "well-tolerated" in previous clinical trials, with no significant safety concerns raised.
  • Ongoing Clinical Trial Risks: The company failed to disclose potential safety issues in the STRIDES Phase 2 trial, particularly elevated liver enzyme levels indicating transaminitis, a warning sign of possible organ damage.

These alleged misrepresentations gave investors an inaccurate picture of the safety and viability of the company's lead product, azelaprag, and clinical development program.

Effects on Stock Prices
The truth began to emerge on December 6, 2024, when BioAge announced it was discontinuing the STRIDES Phase 2 study due to safety concerns, including elevated liver enzyme levels in trial participants.

As a result:

  • Stock Price Crash: Following the announcement, the company’s stock plummeted by $15.44 per share—more than 76%.
  • Ongoing Decline: By the time the lawsuit was filed, BioAge shares were trading around $5.36, significantly below the IPO price of $18.
  • Investor Losses: Many shareholders experienced substantial financial losses due to the dramatic decline in stock value.

Legal Rights for Affected Shareholders
Shareholders who purchased BioAge stock during or shortly after the IPO and suffered losses may have legal grounds to seek compensation. The lawsuit alleges that the company violated securities laws by misrepresenting the safety profile of azelaprag and concealing material risks.

By joining this class action, affected shareholders can:

  • Pursue financial recovery for their losses tied to BioAge stock.
  • Hold the company accountable for its alleged misstatements and omissions.
  • Demand greater transparency in future public disclosures.

If you purchased BioAge shares and experienced financial harm, you may qualify to participate in this case.

Take Action Today
Protect your rights by acting quickly. Contact legal professionals experienced in securities fraud cases to explore your options and ensure your claim is filed before the legal deadline.

By joining the BioAge class action, you align with other affected investors to seek justice and fair compensation. Time is of the essence—take the first step today to safeguard your legal rights.

iStock-2021524839

DiCello Levitt Fights to Protect Shareholder Rights  

At DiCello Levitt, we defend shareholders like you against deceptive corporate practices. With a proven track record in class action lawsuits, we will work tirelessly to secure the compensation you deserve.  

Here's how we can help:  

  1. Conduct a thorough investigation into your claims.  
  2. Build a strong case to hold BioAge® accountable.  
  3. Pursue maximum compensation for your financial losses.  

You don't have to face this fight alone. Contact DiCello Levitt today for a free, private case evaluation. Together, we'll explore your legal options and assess your potential compensation. Take action now to protect your rights and reclaim what you've lost.  

All victims affected by BioAge® alleged deceptive practices and failure to meet basic compliance standards should receive justice and potential compensation, beginning with a free, private case review with our experienced legal team.

The Importance of Joining a Class Action

Class action lawsuits can provide an efficient mechanism to compensate injured victims, hold wrongdoers accountable, or affect how a company or an industry operates.  Class actions allow injured parties to come together and take on larger adversaries.  By leveraging the power of a group class members the class can match the resources of a corporate defendant and put the parties on equal footing.

If you have been adversely affected by corporate misconduct, you may join DiCello Levitt’s class action lawsuit and help hold the wrongdoers responsible for their alleged misconduct, potentially recover your financial losses, and contribute to enforcing higher ethical, governance, and compliance standards.  Your participation can make a difference.

To learn more about how to join the lawsuit and your potential eligibility, please contact DiCello Levitt.  DiCello Levitt is committed to representing the interests of all affected parties and pursuing justice in this significant case.

Find Out if You may be a Member
of the Class

BioAge Labs Inc.® Class Action

Soto v. BioAge Labs, Inc. et al.

BioAge Labs Inc

NASDAQ: BIOA

Class Period : 09/22/2024 - 01/07/2025

Lead Plaintiff Motion Deadline: 3/10/2025

Alleged Misstatements and Omissions
The BioAge® class action lawsuit claims the company misled investors by making false and/or misleading statements and omitting critical information in its IPO offering documents. Key allegations include:

  • Safety Claims for Azelaprag: The IPO prospectus described the lead drug candidate, azelaprag, as "well-tolerated" in previous clinical trials, with no significant safety concerns raised.
  • Ongoing Clinical Trial Risks: The company failed to disclose potential safety issues in the STRIDES Phase 2 trial, particularly elevated liver enzyme levels indicating transaminitis, a warning sign of possible organ damage.

These alleged misrepresentations gave investors an inaccurate picture of the safety and viability of the company's lead product, azelaprag, and clinical development program.

Effects on Stock Prices
The truth began to emerge on December 6, 2024, when BioAge announced it was discontinuing the STRIDES Phase 2 study due to safety concerns, including elevated liver enzyme levels in trial participants.

As a result:

  • Stock Price Crash: Following the announcement, the company’s stock plummeted by $15.44 per share—more than 76%.
  • Ongoing Decline: By the time the lawsuit was filed, BioAge shares were trading around $5.36, significantly below the IPO price of $18.
  • Investor Losses: Many shareholders experienced substantial financial losses due to the dramatic decline in stock value.

Legal Rights for Affected Shareholders
Shareholders who purchased BioAge stock during or shortly after the IPO and suffered losses may have legal grounds to seek compensation. The lawsuit alleges that the company violated securities laws by misrepresenting the safety profile of azelaprag and concealing material risks.

By joining this class action, affected shareholders can:

  • Pursue financial recovery for their losses tied to BioAge stock.
  • Hold the company accountable for its alleged misstatements and omissions.
  • Demand greater transparency in future public disclosures.

If you purchased BioAge shares and experienced financial harm, you may qualify to participate in this case.

Take Action Today
Protect your rights by acting quickly. Contact legal professionals experienced in securities fraud cases to explore your options and ensure your claim is filed before the legal deadline.

By joining the BioAge class action, you align with other affected investors to seek justice and fair compensation. Time is of the essence—take the first step today to safeguard your legal rights.

iStock-2021524839

DiCello Levitt Fights to Protect Shareholder Rights  

At DiCello Levitt, we defend shareholders like you against deceptive corporate practices. With a proven track record in class action lawsuits, we will work tirelessly to secure the compensation you deserve.  

Here's how we can help:  

  1. Conduct a thorough investigation into your claims.  
  2. Build a strong case to hold BioAge® accountable.  
  3. Pursue maximum compensation for your financial losses.  

You don't have to face this fight alone. Contact DiCello Levitt today for a free, private case evaluation. Together, we'll explore your legal options and assess your potential compensation. Take action now to protect your rights and reclaim what you've lost.  

All victims affected by BioAge® alleged deceptive practices and failure to meet basic compliance standards should receive justice and potential compensation, beginning with a free, private case review with our experienced legal team.

The Importance of Joining a Class Action

Class action lawsuits can provide an efficient mechanism to compensate injured victims, hold wrongdoers accountable, or affect how a company or an industry operates.  Class actions allow injured parties to come together and take on larger adversaries.  By leveraging the power of a group class members the class can match the resources of a corporate defendant and put the parties on equal footing.

If you have been adversely affected by corporate misconduct, you may join DiCello Levitt’s class action lawsuit and help hold the wrongdoers responsible for their alleged misconduct, potentially recover your financial losses, and contribute to enforcing higher ethical, governance, and compliance standards.  Your participation can make a difference.

To learn more about how to join the lawsuit and your potential eligibility, please contact DiCello Levitt.  DiCello Levitt is committed to representing the interests of all affected parties and pursuing justice in this significant case.

100% Free & Secure Case Evaluations

Answer a few basic questions to get started

We'll ask specific questions to understand the situation, damage risk, and other vital information to help determine the next steps.

Receive a confidential evaluation

A qualified legal team led by a Financial Products Litigation attorney will consider the facts of your case.

BioAge® Investors may have grounds to pursue legal action and financial recovery of damages.

This website offers general information only and is not legal or investment advice. This advertisement is not associated with any government agency.

www.stockfraudclaim.com is the property of Shield Legal LLC. 5170 Badura Ave Las Vegas, NV 89118

Participating law firm: DiCello Levitt LLP, 10 North Dearborn Street Sixth Floor Chicago, IL 60602. For additional terms, disclaimers, and conditions, please visit https://dicellolevitt.com/privacy-policy/

This website is not part of the Facebook website or Facebook, Inc., and it is NOT endorsed by Facebook in any way. FACEBOOK is a trademark of Facebook, Inc.

ATTORNEY ADVERTISING. This Website does not provide investment, legal, or medical advice. Every case is evaluated on its facts and circumstances. Valuation depends on facts, injuries, jurisdiction, venue, witnesses, parties, and testimony, among other factors. No representation is made that the quality of legal services to be performed is greater than the quality of legal services performed by other lawyers. Stock Fraud Claim does not itself provide legal services. Cases will be referred to third-party attorneys and law firms.  Court costs and case expenses may be the responsibility of the client. Not available in all states. This advertisement is not intended as a testimonial, endorsement, or dramatization and does not constitute a guarantee, warranty, or prediction regarding the outcome of your legal matter, either expressed or implied. Anyone considering a lawyer should independently investigate the lawyer's credentials and ability, and not rely upon advertisements or self-proclaimed expertise. Only persons age 18 or older have permission to access our Service. Our Service does not address anyone under 13 ("Children").

NO ATTORNEY-CLIENT RELATIONSHIP. Use of this website, including sending or receiving information through it, does not establish an attorney-client relationship, nor is any non-passworded information considered privileged or confidential. No class has been certified.  Until a case is filed and a class is certified, you are not represented by counsel unless you retain one.  You may select counsel of your choice.  An attorney-client relationship with DiCello Levitt is established only by an express written agreement signed by DiCello Levitt to represent you.

Attorney Advertising.  Prior results do not guarantee a similar outcome.

Privacy Policy | Terms and Conditions | CCPA Privacy Notice | Do Not Sell My Info

©2024 Stock Fraud Claim. All Rights Reserved